The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
 
Ian Flinn
Consulting or Advisory Role - Abbvie (Inst); Seagen (Inst); TG Therapeutics (Inst); Verastem (Inst)
Research Funding - Abbvie (Inst); Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Curis (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Juno Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Merck (Inst); MorphoSys (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Takeda (Inst); Teva (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
Michael Marris
No Relationships to Disclose
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Cyclacel; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Loxo; miRagen; Oncternal Therapeutics, Inc; Pharmacyclics; Sunesis Pharmaceuticals; Xencor
 
Steven Coutre
Stock and Other Ownership Interests - Pharmacyclics (I)
Consulting or Advisory Role - Abbvie; BeiGene; Celgene; Genentech/Roche; Gilead Sciences; Janssen Oncology; Novartis; Pharmacyclics
Research Funding - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Celgene (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Millenium Pharamceuticals (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - abbvie; BeiGene; Celgene; Gilead Sciences; Janssen Oncology; Novartis; Pharmacyclics
 
John M. Pagel
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics
 
John C. Byrd
Consulting or Advisory Role - Acerta Pharma; Genentech; Jazz Pharmaceuticals; Pharmacyclics
Research Funding - Acerta Pharma (Inst); Genentech (Inst); Janssen (Inst); Pharmacyclics (Inst)
 
Lovely Goyal
Employment - Kite, a Gilead company
 
Krista Goodman
Employment - Kite, a Gilead company
 
Yan Zheng
Employment - Kite, a Gilead company
 
Francesca Milletti
Employment - Kite, a Gilead company; Roche
Stock and Other Ownership Interests - Kite, a Gilead company; Roche
Research Funding - Gilead Sciences; Roche
Patents, Royalties, Other Intellectual Property - Roche
Travel, Accommodations, Expenses - Gilead Sciences; Roche
 
Swaminathan Murugappan
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Gilead Sciences
 
Jennifer R. Brown
Honoraria - Abbvie; Janssen Oncology
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Celgene; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Pharmacyclics; Redx Pharma; Roche/Genentech; Sun Pharma
Research Funding - Gilead Sciences